Economic impact of antimicrobial resistance

One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Stud...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2001-03, Vol.7 (2), p.286-292
Main Author: McGowan, Jr, J E
Format: Article
Language:English
Subjects:
Analysis
Drug resistance in microorganisms
Drug Resistance, Microbial
Economic aspects
Economic research
Health Care Costs
Humans
Public Health - legislation & jurisprudence
Public Opinion
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c623t-a4d1b68e87ad9e25b44fc3da82d0948f97d3d1fd0d64ff9f675170a1f023655f3
cites cdi_FETCH-LOGICAL-c623t-a4d1b68e87ad9e25b44fc3da82d0948f97d3d1fd0d64ff9f675170a1f023655f3
container_end_page 292
container_issue 2
container_start_page 286
container_title Emerging infectious diseases
container_volume 7
creator McGowan, Jr, J E
description One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Studies to describe and evaluate the problem will have to employ new methods and be of large scale to produce information that is broadly applicable.
doi_str_mv 10.3201/eid0702.010228
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2631707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A73889946</galeid><sourcerecordid>A73889946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c623t-a4d1b68e87ad9e25b44fc3da82d0948f97d3d1fd0d64ff9f675170a1f023655f3</originalsourceid><addsrcrecordid>eNqNks9rFDEUx4MotlavHmUviqCzvvyYyeQilNJqoVDw1zVkk5fdyEyyTjKi_31Tdqld6EFySHj5vM_hvS8hLyksOQP6AYMDCWwJFBjrH5FjCj00HbTq8d1bwBF5lvNPAFpb1FNyRClTQrL2mLw7tymmMdhFGLfGlkXyCxNLqJUprYIZFhPmkIuJFp-TJ94MGV_s7xPy_eL829nn5ur60-XZ6VVjO8ZLY4Sjq67HXhqnkLUrIbzlzvTMgRK9V9JxR70D1wnvle9kSyUY6oHxrm09PyEfd97tvBrRWYxlMoPeTmE001-dTNCHPzFs9Dr91qzj1SSr4M1eMKVfM-aix5AtDoOJmOaspQQhFL0F3-_AtRlQh-hT9dk1RqzaFNGHWj6VvO-VEl3FmwfwehzWeT3Evz3gK1LwT1mbOWd9-fXLf6PXPw7Q1_fQDZqhbHIa5hJSzAfccsfVTeY8ob-bIAV9Gx69D4_ehac2vLo_93_4Pi38BojrvbA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77044917</pqid></control><display><type>article</type><title>Economic impact of antimicrobial resistance</title><source>PubMed Central</source><creator>McGowan, Jr, J E</creator><creatorcontrib>McGowan, Jr, J E</creatorcontrib><description>One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Studies to describe and evaluate the problem will have to employ new methods and be of large scale to produce information that is broadly applicable.</description><identifier>ISSN: 1080-6040</identifier><identifier>EISSN: 1080-6059</identifier><identifier>DOI: 10.3201/eid0702.010228</identifier><identifier>PMID: 11294725</identifier><language>eng</language><publisher>United States: U.S. National Center for Infectious Diseases</publisher><subject>Analysis ; Drug resistance in microorganisms ; Drug Resistance, Microbial ; Economic aspects ; Economic research ; Health Care Costs ; Humans ; Public Health - legislation &amp; jurisprudence ; Public Opinion</subject><ispartof>Emerging infectious diseases, 2001-03, Vol.7 (2), p.286-292</ispartof><rights>COPYRIGHT 2001 U.S. National Center for Infectious Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c623t-a4d1b68e87ad9e25b44fc3da82d0948f97d3d1fd0d64ff9f675170a1f023655f3</citedby><cites>FETCH-LOGICAL-c623t-a4d1b68e87ad9e25b44fc3da82d0948f97d3d1fd0d64ff9f675170a1f023655f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631707/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631707/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11294725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McGowan, Jr, J E</creatorcontrib><title>Economic impact of antimicrobial resistance</title><title>Emerging infectious diseases</title><addtitle>Emerg Infect Dis</addtitle><description>One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Studies to describe and evaluate the problem will have to employ new methods and be of large scale to produce information that is broadly applicable.</description><subject>Analysis</subject><subject>Drug resistance in microorganisms</subject><subject>Drug Resistance, Microbial</subject><subject>Economic aspects</subject><subject>Economic research</subject><subject>Health Care Costs</subject><subject>Humans</subject><subject>Public Health - legislation &amp; jurisprudence</subject><subject>Public Opinion</subject><issn>1080-6040</issn><issn>1080-6059</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqNks9rFDEUx4MotlavHmUviqCzvvyYyeQilNJqoVDw1zVkk5fdyEyyTjKi_31Tdqld6EFySHj5vM_hvS8hLyksOQP6AYMDCWwJFBjrH5FjCj00HbTq8d1bwBF5lvNPAFpb1FNyRClTQrL2mLw7tymmMdhFGLfGlkXyCxNLqJUprYIZFhPmkIuJFp-TJ94MGV_s7xPy_eL829nn5ur60-XZ6VVjO8ZLY4Sjq67HXhqnkLUrIbzlzvTMgRK9V9JxR70D1wnvle9kSyUY6oHxrm09PyEfd97tvBrRWYxlMoPeTmE001-dTNCHPzFs9Dr91qzj1SSr4M1eMKVfM-aix5AtDoOJmOaspQQhFL0F3-_AtRlQh-hT9dk1RqzaFNGHWj6VvO-VEl3FmwfwehzWeT3Evz3gK1LwT1mbOWd9-fXLf6PXPw7Q1_fQDZqhbHIa5hJSzAfccsfVTeY8ob-bIAV9Gx69D4_ehac2vLo_93_4Pi38BojrvbA</recordid><startdate>20010301</startdate><enddate>20010301</enddate><creator>McGowan, Jr, J E</creator><general>U.S. National Center for Infectious Diseases</general><general>Centers for Disease Control and Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20010301</creationdate><title>Economic impact of antimicrobial resistance</title><author>McGowan, Jr, J E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c623t-a4d1b68e87ad9e25b44fc3da82d0948f97d3d1fd0d64ff9f675170a1f023655f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Analysis</topic><topic>Drug resistance in microorganisms</topic><topic>Drug Resistance, Microbial</topic><topic>Economic aspects</topic><topic>Economic research</topic><topic>Health Care Costs</topic><topic>Humans</topic><topic>Public Health - legislation &amp; jurisprudence</topic><topic>Public Opinion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McGowan, Jr, J E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Emerging infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McGowan, Jr, J E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Economic impact of antimicrobial resistance</atitle><jtitle>Emerging infectious diseases</jtitle><addtitle>Emerg Infect Dis</addtitle><date>2001-03-01</date><risdate>2001</risdate><volume>7</volume><issue>2</issue><spage>286</spage><epage>292</epage><pages>286-292</pages><issn>1080-6040</issn><eissn>1080-6059</eissn><abstract>One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Studies to describe and evaluate the problem will have to employ new methods and be of large scale to produce information that is broadly applicable.</abstract><cop>United States</cop><pub>U.S. National Center for Infectious Diseases</pub><pmid>11294725</pmid><doi>10.3201/eid0702.010228</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1080-6040
ispartof Emerging infectious diseases, 2001-03, Vol.7 (2), p.286-292
issn 1080-6040
1080-6059
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2631707
source PubMed Central
subjects Analysis
Drug resistance in microorganisms
Drug Resistance, Microbial
Economic aspects
Economic research
Health Care Costs
Humans
Public Health - legislation & jurisprudence
Public Opinion
title Economic impact of antimicrobial resistance
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A24%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Economic%20impact%20of%20antimicrobial%20resistance&rft.jtitle=Emerging%20infectious%20diseases&rft.au=McGowan,%20Jr,%20J%20E&rft.date=2001-03-01&rft.volume=7&rft.issue=2&rft.spage=286&rft.epage=292&rft.pages=286-292&rft.issn=1080-6040&rft.eissn=1080-6059&rft_id=info:doi/10.3201/eid0702.010228&rft_dat=%3Cgale_pubme%3EA73889946%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c623t-a4d1b68e87ad9e25b44fc3da82d0948f97d3d1fd0d64ff9f675170a1f023655f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77044917&rft_id=info:pmid/11294725&rft_galeid=A73889946&rfr_iscdi=true